Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-07-01 18:47:19 ET · period of report 2026-06-29 · accession 0001995218-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 18:47 | 2026-06-29 | LXEO | Townsend Richard Nolan | CEO, Dir | A - Grant | $0.00 | +67.0K | 403.8K | +20% | $0 | |
| 2026-07-01 18:47 | 2026-07-01 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale | $4.48 | -25.9K | 377.8K | -6% | -$116.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | A | A | 67,000 | $0.00 | 403,764 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 25,947 | $4.48 | 377,817 | D | — | — | (F1) Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs"). (F2) This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 252,130 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. |